NRXP · NRX Pharmaceuticals, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $3.39M | $1.23M | $0 | $0 | — | — | — | — | — | |
| $25.78K | — | — | — | — | — | $138.76K | $1.21M | $1.09M | |
| $1.81M | $505K | $0 | — | — | — | — | — | — | |
| $1.58M | $720K | $0 | — | — | — | — | — | — | |
| — | 58.78% | — | — | — | — | — | — | — | |
| $5.41M | $3.78M | $6.2M | $13.37M | $17.03M | $20.26M | $10.63M | — | — | |
| — | — | $13.51M | $14.22M | $27.31M | $74.94M | $11.44M | — | — | |
| $15.93M | $13.06M | $13.5M | — | — | — | — | — | — | |
| $198K | $70K | $5000 | — | — | — | — | — | — | |
| — | — | $18.5M | $27.84M | $44.34M | $115.8M | $51.39M | $713.19K | $1.01M | |
| $23.29M | $17.45M | $18.5M | — | — | — | — | — | — | |
| -$19.89M | -$16.22M | -$18.5M | -$27.84M | -$44.34M | -$115.8M | -$51.39M | -$713.19K | -$1.01M | |
| — | -1324.41% | — | — | — | — | — | — | — | |
| -$19.7M | -$16.15M | -$18.5M | — | — | — | — | — | — | |
| $1.14M | $671K | $230K | $120K | — | $18K | $56K | — | — | |
| $17K | $12K | $44K | $494K | — | — | — | — | — | |
| -$3.59M | -$12.4M | -$6.62M | -$2.31M | $4.58M | $22.73M | -$390K | $1.21M | $1.09M | |
| — | $35K | $0 | — | — | — | — | — | — | |
| — | — | — | — | -$39.75M | -$93.06M | -$51.78M | $492.63K | $82.41K | |
| $0 | $0 | $0 | $0 | — | — | $17.84K | $84.21K | $16.31K | |
| -$23.48M | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M | -$51.78M | $408.43K | $66.1K | |
| — | -2336.49% | — | — | — | — | — | — | — | |
| — | — | -$25.13M | -$30.16M | -$39.75M | -$348.89M | -$51.78M | -$295.47K | -$748.86K | |
| — | — | -$25.13M | -$30.15M | — | — | — | — | — | |
| USD/shares | -$0.50 | -$1.34 | -$2.36 | -$3.98 | -$6.00 | -$19.80 | -$15.10 | — | — |
| USD/shares | — | — | — | — | -$6.00 | -$19.80 | -$15.10 | — | — |
| shares | — | 21.4M | 10.64M | 7.58M | 6.58M | 4.69M | 3.43M | 278.3K | 261.45K |
| shares | — | — | — | — | 6.58M | 4.69M | 3.43M | 278.3K | 261.45K |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 301 similar-size Biotechnology companies (of 537 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 |
|---|---|
| Therapy | $854,000 |
| Procedures | $371,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 |
|---|---|
| Dura Segment | -$87,000 |
| Nrx Segment | -$16,137,000 |